No Data
No Data
Here's Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing
Cidara Therapeutics Announces Leadership Changes and Appointments
Cidara Therapeutics Files Secondary Stock Sale Statement
RBC Capital Initiates Cidara Therapeutics(CDTX.US) With Buy Rating, Announces Target Price $34
RBC Initiates Cidara Therapeutics at Outperform, Speculative Risk, With $34 Price Target
WBB Securities Initiates Cidara Therapeutics(CDTX.US) With Buy Rating, Announces Target Price $45